WO2003038056A3 - Methods for inhibiting lentivirus replication - Google Patents

Methods for inhibiting lentivirus replication Download PDF

Info

Publication number
WO2003038056A3
WO2003038056A3 PCT/US2002/035110 US0235110W WO03038056A3 WO 2003038056 A3 WO2003038056 A3 WO 2003038056A3 US 0235110 W US0235110 W US 0235110W WO 03038056 A3 WO03038056 A3 WO 03038056A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
vpr
cis
protein
lentivirus
Prior art date
Application number
PCT/US2002/035110
Other languages
French (fr)
Other versions
WO2003038056A2 (en
Inventor
Michael Sherman
Warner C Greene
Ulrich Schubert
Victor Wray
Uwe Tessmer
Peter Henklein
Karsten Bruns
Original Assignee
Univ California
Michael Sherman
Warner C Greene
Ulrich Schubert
Victor Wray
Uwe Tessmer
Peter Henklein
Karsten Bruns
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California, Michael Sherman, Warner C Greene, Ulrich Schubert, Victor Wray, Uwe Tessmer, Peter Henklein, Karsten Bruns filed Critical Univ California
Priority to AU2002363249A priority Critical patent/AU2002363249A1/en
Publication of WO2003038056A2 publication Critical patent/WO2003038056A2/en
Publication of WO2003038056A3 publication Critical patent/WO2003038056A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/533—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving isomerase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • G01N2333/163—Regulatory proteins, e.g. tat, nef, rev, vif, vpu, vpr, vpt, vpx
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention provides screening methods for identifying a compound that induces loss of the lentiviral protein Vpr; screening methods for identifying compounds that inhibit the peptidyl-prolyl cis/trans isomerase (PPIase) activity of a protein that catalyzes cis-trans isomerization of cis-peptidylprolyl bonds in Vpr; and compounds identified by the screening methods. The compounds are useful for treating a lentiviral infection. The present invention further provides methods of inducing loss of the lentiviral protein Vpr; methods of inhibiting lentivirus viral replication; and methods of treating a lentivirus infection in an individual. The methods generally involve administering to an individual infected with the lentivirus an effective amount of a compound that induces Vpr loss and/or that inhibits PPIase activity of a protein that catalyzes cis-trans isomerization of cis-peptidylprolyl bonds in Vpr.
PCT/US2002/035110 2001-11-02 2002-10-31 Methods for inhibiting lentivirus replication WO2003038056A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002363249A AU2002363249A1 (en) 2001-11-02 2002-10-31 Methods for inhibiting lentivirus replication

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35016801P 2001-11-02 2001-11-02
US60/350,168 2001-11-02

Publications (2)

Publication Number Publication Date
WO2003038056A2 WO2003038056A2 (en) 2003-05-08
WO2003038056A3 true WO2003038056A3 (en) 2003-09-18

Family

ID=23375498

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/035110 WO2003038056A2 (en) 2001-11-02 2002-10-31 Methods for inhibiting lentivirus replication

Country Status (3)

Country Link
US (1) US7108988B2 (en)
AU (1) AU2002363249A1 (en)
WO (1) WO2003038056A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1439853A2 (en) * 2001-10-25 2004-07-28 Hans Will Means for inhibition of lentiviruses
US20050043253A1 (en) * 2003-08-19 2005-02-24 Cook Bradley R. Use of wound healing compositions for prevention of infections and allergies
WO2010134975A2 (en) * 2009-05-18 2010-11-25 The Scripps Research Institute Methods for enhancing infectivity of retroviruses

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639598A (en) * 1994-05-19 1997-06-17 The Trustees Of The University Of Pennsylvania Method and kit for identification of antiviral agents capable of abrogating HIV Vpr-Rip-1 binding interactions
US5976786A (en) * 1995-12-29 1999-11-02 National Jewish Medical And Research Center Screening methods for the identification of compounds that modulate apoptosis in immunodeficiency virus infected cells

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4814323A (en) 1986-03-25 1989-03-21 Andrieu J M Process for the treatment and the prevention of AIDS and other disorders induced by the LAV/HTLV III virus
US5604092A (en) 1988-12-05 1997-02-18 The Trustees Of Columbia University In The City Of New York Method for the detection of HIV-1 using a cyclosporine-specific monoclonal antibody that reacts with the P24 Gag protein
US5612018A (en) 1989-05-05 1997-03-18 Systemix, Inc. Drug screening and treatment for HIV thymocyte depletion
DE69124459T3 (en) 1990-11-02 2001-05-31 Novartis Ag Cyclosporine
EP0624093A1 (en) 1992-01-28 1994-11-17 KARPAS, Abraham The use of a compound for the manufacture of a medicament for the treatment of hiv infection
US5773225A (en) 1994-05-24 1998-06-30 The Trustees Of Columbia University In The City Of New York Screening method for the identification of compounds capable of abrogation HIV-1 gag-cyclophilin complex formation
KR100441220B1 (en) 1995-07-17 2005-02-24 체-헴 아게 Cyclosporine derivatives with anti-HIV effect
JP2000510097A (en) 1996-03-12 2000-08-08 ザ ピコワー インスティテュート フォー メディカル リサーチ Treatment of HIV infection by interfering with host cell cyclophilin receptor activity
US5840305A (en) 1996-03-14 1998-11-24 The Picower Institute For Medical Research Treatment of HIV-Infection by interfering with host cell cyclophilin receptor activity
AU9203898A (en) 1997-08-26 1999-03-16 Wisconsin Alumni Research Foundation Cyclosporin a conjugates and uses therefor
US6270957B1 (en) 1997-08-26 2001-08-07 Wisconsin Alumni Research Foundation Non-Imuunosuppressive cyclosporins and their use in the prevention and treatment of HIV infection
US6030825A (en) 1998-08-19 2000-02-29 Incyte Pharmaceuticals, Inc. Cyclophilin-type peptidyl-prolyl cis/trans isomerase
AUPP584198A0 (en) 1998-09-14 1998-10-08 Fujisawa Pharmaceutical Co., Ltd. New use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639598A (en) * 1994-05-19 1997-06-17 The Trustees Of The University Of Pennsylvania Method and kit for identification of antiviral agents capable of abrogating HIV Vpr-Rip-1 binding interactions
US5976786A (en) * 1995-12-29 1999-11-02 National Jewish Medical And Research Center Screening methods for the identification of compounds that modulate apoptosis in immunodeficiency virus infected cells

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LIU ET AL.: "Peptidyl-prolyl cis-trans-isomerase from escherichia coli: a periplasmic homolog of cyclophilin that is not inhibited by cyclosporin A", PROC. NATL. ACAD. SCI. USA, vol. 87, no. 11, June 1990 (1990-06-01), pages 4028 - 4032, XP002966102 *
SHERMAN ET AL.: "Nucleocytoplasmic shuttling by human immunodeficiency virus type 1 Vpr", JOURNAL OF VIROLOGY, vol. 75, no. 3, February 2001 (2001-02-01), pages 1522 - 1532, XP002966101 *
ZHAO ET AL.: "Cyclophilin a complexed with a fragment of HIV-1 gag protein: insights into HIV-1 infectous activity", STRUCTURE, vol. 5, no. 1, January 1997 (1997-01-01), pages 139 - 146, XP002966103 *

Also Published As

Publication number Publication date
US7108988B2 (en) 2006-09-19
WO2003038056A2 (en) 2003-05-08
US20040009909A1 (en) 2004-01-15
AU2002363249A1 (en) 2003-05-12

Similar Documents

Publication Publication Date Title
HUP0401542A2 (en) Use of follistatin to increase muscle mass
NO20042964L (en) Spiroazacyclic compounds as monoamine receptor modulators
WO2004060308A3 (en) Thiosemicarbazones as anti-virals and immunopotentiators
WO2003101397A3 (en) Tetravalent dengue vaccines
WO2003051272A3 (en) METHODS AND PHARMACEUTICAL COMPOSITIONS FOR GnRH-I AND GnRH-II MODULATION OF T-CELL ACTIVITY, ADHESION, MIGRATION AND EXTRAVASATION
DK0973735T3 (en) Polyaromatic antiviral preparations
WO2003080566A3 (en) Hif hydroxylase inhibitors
DK0766682T3 (en) Protein kinase C inhibitors
WO2007047725A3 (en) Methods for treating disorders associated with hyperlipidemia in a mammal
MX340217B (en) Method of treatment and bioassay involving macrophage migration inhibitory factor (mif) as cardiac-derived myocardial depressant factor.
AU4837193A (en) Fibrinogen binding protein
AU6790087A (en) Modification of plant viruses or their effects
WO2003015708A8 (en) Composition and method for treating hiv infection
ATE251667T1 (en) VIRUS THAT CAUSES PANCREAS DISEASE IN FISH
WO2003038056A3 (en) Methods for inhibiting lentivirus replication
AU2001258373A1 (en) Method for identifying helicobacter antigens
HUP0002644A2 (en) Phartmaceutical compositions comprising an aldose reductase inhibitor and an ace inhibitor
WO2003097089A3 (en) Attenuation of metapneumovirus
WO2003053332A3 (en) Composition and method for treating viral infection
WO2004028473A3 (en) Synergistic compositions for the prevention and treatment of acquired immunodeficiency syndrome
WO2003037247A3 (en) Methods and pharmaceutical compositions for dopaminergic modulation of t-cell adhesion and acitivty
AU758139C (en) Microparticles produced from cyclic olefin copolymers and their use for the controlled release of active agents
WO2004031209A3 (en) Anti-tsg101 antibodies and their uses for treatment of viral infections
WO2002067984A3 (en) Materials and methods for detecting, preventing, and treating hiv and fiv retroviral infection
WO1993014760A3 (en) Methods

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP